Pentixapharm Holding AG (XTER:PTP) ROCE % : -5.70% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pentixapharm Holding AG's annualized ROCE % for the quarter that ended in Jun. 2024 was -5.70%.

Pentixapharm Holding AG ROCE % Historical Data

The historical data trend for Pentixapharm Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG ROCE % Chart

Pentixapharm Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-6.04

-1.93

-10.40

Pentixapharm Holding AG Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24
ROCE %	-	-	-7.76	-12.53	-5.70

Pentixapharm Holding AG ROCE % Calculation

Pentixapharm Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6.031	/	( ( (53.876 - 1.842)	+	(73.398 - 9.397) )	/ 2 )
	=	-6.031	/	( (52.034	+	64.001)	/ 2 )
	=	-6.031	/	58.0175
	=	-10.40 %

Pentixapharm Holding AG's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-3.596	/	( ( (73.398 - 9.397)	+	(68.939 - 6.69) )	/ 2 )
	=	-3.596	/	( ( 64.001	+	62.249 )	/ 2 )
	=	-3.596	/	63.125
	=	-5.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Pentixapharm Holding AG (XTER:PTP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pentixapharm Holding AG ROCE % Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pentixapharm Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Robert-Rossle-Street 10, Berlin, DEU

Website

https://www.pentixapharm.com

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines